199 related articles for article (PubMed ID: 12764397)
1. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?
Beevers DG; Lee KW; Lip GY
J Hum Hypertens; 2003 Jun; 17(6):367-72. PubMed ID: 12764397
[No Abstract] [Full Text] [Related]
2. ALLHAT: a saga of missed opportunities.
McInnes GT
J Hum Hypertens; 2003 Jun; 17(6):373-7. PubMed ID: 12764398
[No Abstract] [Full Text] [Related]
3. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: focus on the diabetic patient.
Berecek KH; Farag A; Bahtiyar G; Rothman J; McFarlane SI
Curr Hypertens Rep; 2004 Jun; 6(3):212-4. PubMed ID: 15128474
[No Abstract] [Full Text] [Related]
4. [Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
Düsing R
Dtsch Med Wochenschr; 2003 Jan; 128(5):214-6. PubMed ID: 12557115
[No Abstract] [Full Text] [Related]
5. A family physician questions the conclusions from ALLHAT.
Standridge JB
Am J Hypertens; 2004 Apr; 17(4):361-5. PubMed ID: 15062891
[TBL] [Abstract][Full Text] [Related]
6. ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.
Elliott WJ
Am J Hypertens; 1996 Apr; 9(4 Pt 1):409-11. PubMed ID: 8722446
[No Abstract] [Full Text] [Related]
7. The design of ALLHAT may have biased the study's outcome in favor of the diuretic cohort.
Hebert LA; Rovin BH; Hebert CJ
Nat Clin Pract Nephrol; 2007 Feb; 3(2):60-1. PubMed ID: 17251990
[No Abstract] [Full Text] [Related]
8. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
Xie F; Petitti DB; Chen W
Am J Hypertens; 2005 Apr; 18(4 Pt 1):464-9. PubMed ID: 15831354
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
[TBL] [Abstract][Full Text] [Related]
10. [After the ALLHAT trial, what do we know about treatment for hypertension that we did not know before?].
González-Juanatey JR
Rev Esp Cardiol; 2003 Jul; 56(7):642-8. PubMed ID: 12855144
[No Abstract] [Full Text] [Related]
11. [ALLHAT].
Ando K
Nihon Rinsho; 2006 Aug; 64 Suppl 6():402-7. PubMed ID: 16981570
[No Abstract] [Full Text] [Related]
12. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue.
Cardinal H; Monfared AA; Dorais M; LeLorier J
Can J Cardiol; 2004 Mar; 20(4):417-21. PubMed ID: 15057318
[TBL] [Abstract][Full Text] [Related]
13. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
[TBL] [Abstract][Full Text] [Related]
14. Letter by barrios et Al regarding article, "heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial".
Barrios V; Escobar C; Echarri R
Circulation; 2009 Aug; 120(5):e31; author reply e32. PubMed ID: 19652116
[No Abstract] [Full Text] [Related]
15. The hidden effects of antihypertensive and lipid-lowering agents on the prevention and regression of atherogenesis: new management strategies.
Weinberg MS
R I Med; 1995 Mar; 78(3):78-81. PubMed ID: 7734758
[No Abstract] [Full Text] [Related]
16. ALLHAT: definitive answers or continuing uncertainty?
Sever P;
J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):3-5. PubMed ID: 12692746
[No Abstract] [Full Text] [Related]
17. Antihypertensive and lipid lowering treatment in stroke prevention: current state and future.
Piechowski-Jóźwiak B; Bogousslavsky J
Acta Neurol Belg; 2005 Jun; 105(2):57-61. PubMed ID: 16076057
[TBL] [Abstract][Full Text] [Related]
18. Letter by Ben-Dov and Bursztyn regarding article, "Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial".
Ben-Dov IZ; Bursztyn M
Circulation; 2007 Jan; 115(2):e18; author reply e19. PubMed ID: 17228008
[No Abstract] [Full Text] [Related]
19. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A;
J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008
[TBL] [Abstract][Full Text] [Related]
20. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
Motz W
MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487
[No Abstract] [Full Text] [Related]
[Next] [New Search]
